Traditional Chinese medicine composition for improving cognitive impairment of coronary heart disease and application thereof

Abstract

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving cognitive impairment of coronary heart disease and application thereof. The composition is prepared from the following raw material components: fructus alpiniae oxyphyllae, fructus lycii, diaphragma juglandis, lotus plumule, ginseng, ligusticum wallichii and radix paeoniae rubra. The composition can improve the cardiac function and the cardiac structure after coronary heart disease acute myocardial ischemia injury, reduce the ischemic myocardial infarction area, relieve myocardial cell injury and myocardial fibrosis, relieve hippocampal neuron injury and ultrastructure change, and improve learning and memory functions and cognitive behavior performance.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for improving cognitive impairment of coronary heart disease and application thereof. Background Art

[0002] Cardiovascular disease and cognitive impairment are both major diseases that endanger human health. More and more evidence shows that cardiovascular health closely affects the cognitive health of the brain, and the two are closely related. The cardiovascular event chain (from cardiovascular risk factors to end-stage heart disease such as heart failure) with coronary atherosclerosis as the basic feature has expanded its impact to organs other than the heart, especially the brain and affects cognitive function.

[0003] Cognitive impairment is the impairment of one or more cognitive functions and affects an individual's daily or social abilities. It ranges from mild cognitive impairment to dementia. About 25% of dementia cases can be attributed to cardiovascular risk factors and may be prevented by correcting risk factors. Given that there is still a lack of treatments to modify the course of dementia, prevention and management of cardiovascular disease are important to prevent cognitive impairment and slow the transition from MCI to dementia.

[0004] Existing evidence shows that the risk of cognitive dysfunction in patients with coronary heart disease can increase by 45%, which may be due to the worse vascular risk burden brought by atherosclerotic disease, or it may be due to the direct consequences of cardiac dysfunction on the brain. The risk of dementia in patients with a history of myocardial infarction is 2-5 times that of those without such a history. This may be mainly attributed to chronic cerebral hypoperfusion caused by acute myocardial ischemia, which in turn induces inflammation, oxidative stress, immune response, blood-brain barrier damage, etc., resulting in cognitive impairment, or due to myocardial fibrosis and contractile dysfunction, leading to reduced cardiac output, or myocardial damage leading to the activation of systemic inflammation and neurohumoral factors that directly damage cognitive function. However, the potential biological mechanism of cognitive impairment in coronary heart disease has not been fully elucidated, and there is currently no definite medication answer for the treatment of this disease.

[0005] Western medicine to improve cognitive impairment includes cholinesterase inhibitors, ionotropic glutamate receptor antagonists, calcium ion antagonists, ginkgo leaf extract, nootropics, ergot alkaloid preparations, etc. However, as of now, there is no drug for cognitive impairment in coronary heart disease.

[0006] Traditional Chinese medicine has long recognized the relationship between the heart and the brain, such as "the heart is the monarch's official, from which the spirit comes", "the heart stores the pulse, the pulse houses the spirit", and "the heart and the brain jointly control the spirit". Based on the "holistic concept", traditional Chinese medicine proposed "the heart and the brain are connected", and developed "heart and brain treatment" on the basis of "different diseases treated with the same method". It can be said that "heart and brain treatment" embodies the core of the holistic concept and syndrome differentiation of traditional Chinese medicine, and combines modern medicine's understanding of the pathophysiology of cardiovascular and cerebrovascular diseases, and is based on the background of clinical practice. Under the guidance of this theory, adhering to the academic thought of Academician Chen Keji in treating coronary heart disease and cognitive dysfunction, a formula with remarkable efficacy for cognitive dysfunction of coronary heart disease has been condensed and tailored from many years of repeated clinical practice. It has now been found that it can improve cognitive dysfunction in rats after acute myocardial ischemia injury, in order to provide experimental support for the clinical diagnosis and treatment of this disease. Summary of the invention

[0007] In view of the deficiencies in the prior art, the present invention provides a Chinese medicine composition for improving cognitive impairment in coronary heart disease and application thereof.

[0008] In order to achieve the purpose of the present invention, the technical solution adopted is as follows: A traditional Chinese medicine composition for improving cognitive impairment of coronary heart disease. The raw materials of the composition include the following components: Alpinia oxyphylla, Lycium barbarum, Rhizoma Cibotii, Lotus seed core, Ginseng, Rhizoma Chuanxiong and Paeonia lactiflora.

[0009] The traditional Chinese medicine compound for treating cognitive impairment in coronary heart disease is composed of Alpinia oxyphylla, Lycium barbarum, Fructus schizonepetae, Lotus seed core, Ginseng, Rhizoma Chuanxiong and Paeonia lactiflora.

[0010] Among them, Alpinia oxyphylla is the dried fruit of the ginger plant Alpinia oxyphylla, which can nourish the kidney, consolidate essence and reduce urine, warm the spleen and stop diarrhea, improve complexion and prolong life, and improve memory. Modern pharmacological research has confirmed that it contains a large number of terpenes, flavonoids, steroids and other compounds, which have antioxidant, anti-inflammatory and cognitive impairment effects. Traditional Chinese medicine believes that the essence of cognitive impairment in coronary heart disease is deficiency of the root and excess of the superficial. The blockage of the heart meridian runs through the whole process. The deficiency of the five internal organs is the root, especially the kidney deficiency. As the "Jingyue Complete Book" says: "If the root is weak, the person will be sick, and if the root is defeated, the person will be in danger." The kidney is weak and the function of generating essence is abnormal, the yin and yang are unbalanced, and the evil of turbidity is produced in the body. The brain meridians are blocked, and there is no way to wake up the mind and fill the brain. Over time, heat and wind are generated, and the mind is out of order and cognition is abnormal.

[0011] Lycium barbarum is neutral in nature and belongs to the liver and kidney meridians. "Compendium of Materia Medica" records that it has the effects of nourishing the liver and kidney, improving intelligence and eyesight. It is often used to treat liver and kidney yin deficiency, dizziness and forgetfulness.

[0012] Dividing heart wood, also known as nutcracker and walnut septum, is the diaphragm of the walnut kernel of the genus Juglandia of the Juglandaceae family. The famous kidney-tonifying and anti-aging prescription "Qinggong Shoutao Pills" (created in the reign of Emperor Kangxi) also contains this medicine; it tastes bitter, astringent, and neutral in nature. It enters the spleen and kidney meridians. Its main effects are diuresis and heat-clearing, spleen-strengthening and kidney-strengthening, and sperm-astringing and nocturnal emission. It can improve symptoms such as memory loss, soreness of the waist and knees, tinnitus, deafness, and frequent urination at night.

[0013] Lotus seed core is the green middle root of the mature seed of the lotus plant of the Nymphaeaceae family. It is a food and medicine product with both health care and medicinal value. "Compendium of Materia Medica" records that it has the effect of clearing the heart, relieving heat and eliminating restlessness.

[0014] Ginseng tastes sweet and slightly bitter, is mild in nature, and enters the spleen, lung, and heart meridians. It has the effects of replenishing qi, strengthening the body, promoting the production of body fluids, calming the mind, and improving intelligence. It is often used to treat cardiovascular and cerebrovascular diseases, chronic fatigue syndrome, diabetes, neurodegenerative diseases, and many other diseases. The "Shennong's Herbal Classic" says that it can "replenish the five internal organs, calm the spirit, stabilize the soul, stop palpitations, remove evil spirits, improve eyesight, open the heart, and improve intelligence; long-term use of ginseng has been confirmed. The saponin component in ginseng is one of the main components that exert the effects of ginseng, which has the effects of protecting the myocardium, regulating sugar and lipid metabolism, enhancing learning and memory ability, improving cognitive function, and protecting the nervous system.

[0015] Red peony root can promote blood circulation, disperse blood stasis and relieve pain, and its nature is relatively cool. "Bencao Jingshu" calls it "the clearest and strongest fragrance, so it can ward off all evil spirits." When combined with Chuanxiong, which can enter the blood and promote Qi circulation, resolve blood stasis and relieve stagnation, it has the right combination of cold and warm properties, and its efficacy is doubled. It can dilate coronary arteries, protect vascular endothelial cells, resist platelet aggregation, and inhibit vascular remodeling.

[0016] Preferably, the raw materials of the composition include the following components by weight: 15-25 parts of Alpinia oxyphylla, 15-25 parts of Lycium barbarum, 15-25 parts of Rhizoma Cibotii, 3-10 parts of lotus seed core, 5-15 parts of ginseng, 5-15 parts of Ligusticum chuanxiong, and 5-15 parts of red peony root.

[0017] Preferably, the raw materials of the composition include the following components by weight: 15-20 parts of Alpinia oxyphylla, 15-20 parts of Lycium barbarum, 15-20 parts of Rhizoma Cibotii, 3-6 parts of lotus seed core, 10-15 parts of ginseng, 10-15 parts of Ligusticum chuanxiong, and 10-15 parts of red peony root.

[0018] Another object of the present invention is to provide a method for preparing the above composition, comprising: Mix Alpinia oxyphylla, wolfberry, Rhizoma Cibotii, lotus seed core, ginseng, Rhizoma Chuanxiong and Rhizoma Paeoniae Rubra, add water and boil to obtain the medicine.

[0019] Preferably, the decoction is performed 1-3 times, and the decoction time for each time is 0.5-1.5 hours.

[0020] Preferably, the amount of water used is 5-10 times the amount of the total medicinal materials.

[0021] Preferably, the decoction is followed by filtration, and the filtrates are combined, concentrated and dried to obtain the product.

[0022] The third object of the present invention is to provide a pharmaceutical preparation, which comprises the above composition and pharmaceutically acceptable excipients.

[0023] Another object of the present invention is to provide the use of the above composition in the preparation of drugs for preventing and treating cardiovascular diseases and / or cognitive impairment after cardiovascular diseases.

[0024] Preferably, the cardiovascular disease includes coronary heart disease, including one or more of chronic coronary syndrome or acute myocardial ischemia / myocardial infarction; and / or the drug can improve cognitive impairment in patients with coronary heart disease, as well as previous unstable angina and myocardial infarction.

[0025] The cardiovascular diseases include coronary heart disease.

[0026] Preferably, the drug can improve cardiac function and cardiac structure after acute myocardial ischemia, and / or reduce the area of ​​ischemic myocardial infarction, and / or alleviate myocardial cell damage and myocardial fibrosis, and / or alleviate hippocampal neuron damage and ultrastructural changes, and / or improve learning and memory function and cognitive behavior performance. Compared with the prior art, the present invention has the following beneficial effects: (1) The red peony root in the formula can promote blood circulation, dissipate blood stasis and relieve pain. It is cool in nature. When combined with Chuanxiong, which can promote blood circulation and relieve stasis, the combination has a good combination of cold and warm properties, and can promote blood circulation and remove blood stasis, doubling the efficacy. Alpinia oxyphylla can nourish the kidney, consolidate essence, reduce urination, warm the spleen and stop diarrhea, and improve complexion and prolong life. Lycium barbarum is neutral in nature and enters the liver and kidney meridians, and can nourish the liver and kidney, improve essence and improve eyesight. Fenxinmu is bitter and astringent in taste and neutral in nature. It enters the spleen and kidney meridians, and can promote urination and clear heat, strengthen the spleen and consolidate the kidney, and stop nocturnal emission. When used together with Alpinia oxyphylla and Lycium barbarum, it can enhance the effects of nourishing the kidney, producing essence, and strengthening the body. In addition, ginseng can protect the heart, improve intelligence, and regulate qi and blood. Lotus seed heart can clear the heart and relieve restlessness, and combined with red peony root can clear the heat in the blood, prevent blood stasis from turning into heat and detoxification. The whole formula has the effects of promoting blood circulation and removing blood stasis, detoxifying and clearing the heart, nourishing the kidney and replenishing deficiency, and improving intelligence and strengthening the body.

[0027] (2) The present invention uses SD rats, a rodent that is easy to operate, reliable in source, and can be replicated on a large scale, to construct a rat model of acute myocardial ischemia and cognitive impairment by ligating the left anterior descending branch of the coronary artery for drug screening. This operation technique is mature and reliable and can be used for drug screening and efficacy evaluation of this disease. The present invention successfully constructed a rat model of acute myocardial ischemia and cognitive impairment, and screened out a Chinese medicine compound that has the effects of improving cardiac function and protecting cognition. The compound is based on the theory of "heart and brain treatment" in traditional Chinese medicine, and the components cooperate with each other to achieve excellent results. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Ultrasound images of rats in the sham operation group.

[0029] Figure 2 Ultrasound images of rats in the model group.

[0030] Figure 3 This is the ultrasonic image of rats in Example 1.

[0031] Figure 4 is the ejection fraction (LVEF) of rats' cardiac ultrasound index; compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0032] Figure 5 is the short axis shortening rate (LVFS) of rat heart ultrasound index; compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01. .

[0033] Figure 6 is the left ventricular end-diastolic diameter (LVIDd) of rats; compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0034] Figure 7 The left ventricular end-systolic diameter (LVIDs) of the rat heart ultrasound index was compared with the blank group. # P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0035] Figure 8 This is a picture of TTC staining of rat heart.

[0036] Fig. 9 The ischemic myocardial infarction area / heart area percentage (%) of rats stained with TTC. Compared with the blank group, #P <0.05, ## P <0.01; compared with the model group, * P <0.05,** P <0.01.

[0037] Fig.10 HE staining and Masson staining of myocardial tissues of rats in each group; A is HE staining, and B is Masson staining.

[0038] Fig.11 is the number of times the rats in each group crossed the platform in the water maze experiment.

[0039] Fig.12 is the distance traveled by each group of rats in the target quadrant.

[0040] Fig.13 is the time spent by rats in each group in the target quadrant.

[0041] Fig.14 The typical swimming paths of the positioning navigation experiment and the space exploration experiment for each group of rats; the red and blue squares represent the starting and ending points of the swimming movement, respectively, and the circle represents the location of the platform.

[0042] Fig.15 Pathological images of CA1 region of hippocampal tissue of rats in each group, where A is HE staining (×100) and B is Nissl staining (×100).

[0043] Fig.16 The synaptic ultrastructure of CA1 region of hippocampal tissue in each group of rats was observed under electron microscope (×20500).

[0044] The unclear parts in the above figures will not affect the understanding of the technical solution of the present invention by those skilled in the art. DETAILED DESCRIPTION

[0045] The present invention will be further described below in conjunction with specific implementation modes.

[0046] Example 1 The present embodiment prescription is as follows: 15 parts of Alpinia oxyphylla, 15 parts of Lycium barbarum, 15 parts of Rhizoma Dioscoreae, 3 parts of Lotus seed core, 10 parts of Ginseng, 10 parts of Rhizoma Chuanxiong, and 10 parts of Radix Paeoniae Rubra.

[0047] The preparation method is: (1) Weigh each component of the Chinese medicine compound and mix well; (2) Add 8 times the volume of water to the mixed Chinese medicinal materials for the first decoction for 1.5 hours, and collect the medicinal liquid after filtering; (3) Add 6 times the volume of water to the residue after the first extraction and boil it for a second time for 1 hour, and collect the liquid after filtering; (4) mixing the two extracted medicinal solutions to obtain a water extract of the Chinese medicinal compound; (5) The water extract is subjected to rotary evaporation to evaporate the water in the water extract and extract a more concentrated medicinal solution in the form of a thick paste. The solution is placed in a container, dried, and crushed into fine powder to obtain a dry paste powder. The dry paste powder is stored in a cool and dry place for future use.

[0048] Example 2 The present embodiment prescription is as follows: 25 parts of Alpinia oxyphylla, 25 parts of Lycium barbarum, 25 parts of Rhizoma Dioscoreae, 10 parts of Lotus seed core, 15 parts of Ginseng, 15 parts of Rhizoma Chuanxiong, and 15 parts of Red Peony Root.

[0049] The preparation method is: (1) Weigh each component of the Chinese medicine compound and mix well; (2) Add 8 times the volume of water to the mixed Chinese medicinal materials for the first decoction for 1.5 hours, and collect the medicinal liquid after filtering; (3) Add 6 times the volume of water to the residue after the first extraction and boil it for a second time for 1 hour, and collect the liquid after filtering; (4) mixing the two extracted medicinal solutions to obtain a water extract of the Chinese medicinal compound; (5) The water extract is subjected to rotary evaporation to evaporate the water in the water extract and extract a more concentrated medicinal solution in the form of a thick paste. The solution is placed in a container, dried, and crushed into fine powder to obtain a dry paste powder. The dry paste powder is stored in a cool and dry place for future use.

[0050] Example 3 The present embodiment prescription is as follows: 20 parts of Alpinia oxyphylla, 20 parts of Lycium barbarum, 20 parts of Rhizoma Dioscoreae, 6 parts of Lotus seed core, 5 parts of Ginseng, 5 parts of Rhizoma Chuanxiong, and 5 parts of Radix Paeoniae Rubra.

[0051] The preparation method is: (1) Weigh each component of the Chinese medicine compound and mix well; (2) Add 8 times the volume of water to the mixed Chinese medicinal materials for the first decoction for 1.5 hours, and collect the medicinal liquid after filtering; (3) Add 6 times the volume of water to the residue after the first extraction and boil it for a second time for 1 hour, and collect the liquid after filtering; (4) mixing the two extracted medicinal solutions to obtain a water extract of the Chinese medicinal compound; (5) The water extract is subjected to rotary evaporation to evaporate the water in the water extract and extract a more concentrated medicinal solution in the form of a thick paste. The solution is placed in a container, dried, and crushed into fine powder to obtain a dry paste powder. The dry paste powder is stored in a cool and dry place for future use.

[0052] Comparative Example 1 The difference from Example 1 is that the formula is different, specifically: 15 parts of Alpinia oxyphylla, 15 parts of Lycium barbarum, 15 parts of Rhizoma Dioscoreae, 3 parts of Ophiopogon japonicus, 10 parts of Ginseng, 10 parts of Ligusticum chuanxiong, and 10 parts of Paeonia lactiflora.

[0053] Comparative Example 2 The difference from Example 1 is that the formula is different, specifically: 15 parts of Alpinia oxyphylla, 15 parts of Lycium barbarum, 15 parts of Psoralea corylifolia, 3 parts of lotus seed core, 10 parts of ginseng, 10 parts of safflower, and 10 parts of peach kernel.

[0054] The above parts are all parts by weight.

[0055] Effect of the Chinese herbal compound of the present invention on myocardial remodeling and cognitive function in rats with acute myocardial ischemia and cognitive impairment Modeling and grouping: The acute myocardial ischemia injury rat model was prepared by surgical ligation of the left anterior descending branch of the coronary artery of SD rats, and the sham operation group was only threaded without ligation. Combined with the electrocardiogram results and postoperative conditions, the rats were grouped into: sham operation group (blank), model group (model), and Example 1 group, with 18 rats in each group.

[0056] Administration and dosage: The yield was calculated according to the dosage conversion method for rats and humans in "Experimental Animals and Animal Experimental Techniques". The oral administration dosage of the composition of Example 1-3 (the present invention's formulation) and Comparative Example 1-2 was 8.19 g / Kg / d [the preparation method of the Chinese medicine compound dry paste powder is the same as described above]. The sham operation group and the model group were given an equal volume of pure water by oral administration. The rats in each group began drug intervention on the second day after modeling, and were weighed once a week, and the dosage was adjusted according to the changes in body weight. The drug intervention continued for 6 weeks.

[0057] Experimental detection: Echocardiography was used to evaluate cardiac structure and function, Morris water maze experiment was used to observe cognitive and behavioral changes, myocardial tissue HE and Masson pathological staining, TTC staining was used to detect ischemic myocardial infarction area, HE and Nissl staining were used to observe hippocampal pathological changes, and transmission electron microscopy was used to observe brain tissue synaptic ultrastructure.

[0058] Experimental results: (1) Echocardiography Figure 1-7 : Compared with the blank group, the LVEF and LVFS of the rats in the model group were significantly decreased ( P <0.01), LVIDd and LVIDs increased significantly ( P<0.01), it can be seen that the ventricular cavity of the model group was dilated and the cardiac function was weakened; compared with the model group, the LVEF and LVFS values ​​of the rats in Example 1 group were significantly increased ( P <0.01), LVIDd and LVIDs values ​​were significantly reduced ( P <0.01).

[0059] (2) Macroscopic view of the heart and the area of ​​ischemic myocardial infarction Figure 8-9 The heart surface of the blank group was smooth, the myocardium was red, the shape was elastic, and no discoloration was observed; the left ventricular infarction area of ​​each surgical ligation group turned white, the myocardium was dark, the ventricular wall was thinned and collapsed, and the ventricular cavity was enlarged, which was most obvious in the model group. TTC staining showed that the infarction area increased significantly ( P <0.01); compared with the model group, the heart morphology, myocardial color and ventricular wall changes in the intervention group of Example 1 were alleviated, and the infarction area was reduced.

[0060] (3) Myocardial tissue pathological morphology results are shown in Fig.10 : HE staining: The myocardial cells of the rats in the blank group were arranged neatly and intact, the myocardial tissue fibers were dense, the transverse striations were clear, and no inflammatory cell infiltration was observed; the myocardial cells of the rats in the model group were disorderly arranged, with extensive necrosis, thickening and rupture of myocardial fibers, and a large number of inflammatory cell infiltrations were observed in the interstitium; compared with the model group, the myocardial damage in the intervention group of Example 1 was less severe, and the inflammatory cell infiltration was reduced.

[0061] Masson staining: In the blank group, the myocardial cells were arranged neatly, and a small amount of collagen fibers were deposited in the myocardial interstitial space; in the model group, a large amount of blue staining and collagen fibers were deposited in the edge area of ​​myocardial infarction, and the myocardial cells were arranged disorderly; compared with the model group, the blue staining area in the intervention group of Example 1 was significantly reduced.

[0062] (4) Cognitive behavioral science: Morris water maze test results are shown in Figure 11-14 : Compared with the blank group, the latency of rats in the model group was significantly prolonged ( P <0.01), the number of platform crossings, the distance and time spent in the target quadrant were significantly reduced ( P <0.01); compared with the model group, the incubation period of the intervention group of Example 1 on the third and fifth days was shortened ( P <0.05), the number of crossing the platform increased (P<0.05), and the activity distance and time in the quadrant where the original platform was located increased significantly.

[0063] Table 1 Escape latency of rats in each group (x ± s)

[0064] Note: Compared with the blank group, # P <0.05, ## P <0.01; compared with the model group, * P <0.05, ** P <0.01.

[0065] (5) The results of brain tissue pathology are shown in Fig.15 : HE staining: The structure of hippocampal tissue in the blank group was normal, the pyramidal cells in the CA1 region were relatively regular circles or ovals, the granule cells and neurons were neatly arranged, tightly connected, plump in shape, and with clear nucleoli; the above cells and neurons in the CA1 region of the hippocampal tissue in the model group were relatively disorderly arranged, with a reduced number, loose gaps, unclear layers, fuzzy cell membranes and nucleoli, and some nuclei were deformed and condensed; compared with the model group, the pathological changes in the hippocampus of the rats in the intervention group of Example 1 were milder, the cell structure was clearer and more complete, and the arrangement was neater and tighter.

[0066] Nissl staining: The cells in the CA1 region of the hippocampus of the rats in the blank group were arranged more neatly, the number of neurons distributed in more layers, the outlines of the nerve cells were clear and complete, and the number of Nissl bodies in the cytoplasm was relatively abundant; the neurons in the hippocampus of the rats in the model group were arranged irregularly, the number of Nissl bodies was significantly reduced or even disappeared, the staining became significantly lighter, and there was nuclear condensation; compared with the model group, the neurons in the Example 1 group were arranged more regularly, the cell outlines were clearer, the Nissl bodies were reduced to a certain extent, and the cytoplasm staining was darker.

[0067] (6) The results of hippocampal synaptic ultrastructure under transmission electron microscopy are shown in Fig.16 : The synaptic structure of the rats in the blank group was clear, the distance and morphology of the synaptic cleft were normal, the contours of the presynaptic and postsynaptic membranes were complete, and more synaptic vesicles were visible in the larger presynaptic swelling; the postsynaptic density zone in the CA1 region of the hippocampus of the rats in the model group was smaller, the morphology was blurred, and the synaptic vesicles were scattered; compared with the model group, the synaptic structure of the CA1 region of the hippocampus of the rats in the Example 1 group was clearer, the presynaptic membrane morphology was normal, and the thickness of the postsynaptic density zone was normal and uniform.

[0068] Conclusion: The prescription of the present invention can improve the cardiac function and cardiac structure of rats after acute myocardial ischemia injury, reduce the area of ​​ischemic myocardial infarction, alleviate myocardial cell damage and myocardial fibrosis, alleviate the damage of hippocampal neurons and ultrastructural changes, and improve learning and memory function and cognitive behavioral performance.

Claims

1. A Chinese medicine composition for improving cognitive impairment in coronary heart disease, It is characterized in that The raw materials of the composition include the following components: Alpinia oxyphylla, Lycium barbarum, Rhizoma Cibotii, Lotus seed core, Ginseng, Rhizoma Chuanxiong and Radix Paeoniae Rubra.

2. The composition according to claim 1, It is characterized in that The raw materials of the composition include the following components by weight: 15-25 parts of Alpinia oxyphylla seeds, 15-25 parts of Lycium barbarum, 15-25 parts of Psoralea corylifolia, 3-10 parts of lotus seed core, 5-15 parts of ginseng, 5-15 parts of Chuanxiong and 5-15 parts of red peony root.

3. The composition according to claim 1, It is characterized in that The raw materials of the composition include the following components by weight: 15-20 parts of Alpinia oxyphylla seeds, 15-20 parts of Lycium barbarum, 15-20 parts of Psoralea corylifolia, 3-6 parts of lotus seed core, 10-15 parts of ginseng, 10-15 parts of Chuanxiong and 10-15 parts of red peony root.

4. A method for preparing the composition according to any one of claims 1 to 3, It is characterized in that The preparation comprises mixing Alpinia oxyphylla, Lycium barbarum, Rhizoma Cibotii, Lotus seed core, Ginseng, Rhizoma Chuanxiong and Rhizoma Paeoniae Rubra, adding water and boiling the mixture.

5. The preparation method according to claim 4, It is characterized in that The number of decoctions is 1-3 times, and the time of each decoction is 0.5-1.5; And / or, the amount of water used is 5-10 times the total amount of medicinal materials.

6. The preparation method according to claim 4, It is characterized in that After decoction, filter, combine the filtrate, concentrate and dry to obtain the product.

7. A pharmaceutical preparation, It is characterized in that The preparation comprises the Chinese medicine composition according to any one of claims 1 to 3 and pharmaceutically acceptable excipients.

8. Use of the traditional Chinese medicine composition according to any one of claims 1 to 3 in the preparation of drugs for preventing and treating cardiovascular diseases and / or cognitive impairment after cardiovascular diseases.

9. The use according to claim 8, It is characterized in that The cardiovascular disease includes one or more of coronary heart disease, including chronic coronary syndrome, and acute myocardial ischemic injury; and / or the drug can improve cognitive impairment in patients with coronary heart disease, as well as previous unstable angina and myocardial infarction.

10. The use according to claim 8, It is characterized in that The drug can improve cardiac function and cardiac structure after acute myocardial ischemia injury, and / or reduce the area of ​​ischemic myocardial infarction, and / or alleviate myocardial cell damage and myocardial fibrosis, and / or alleviate damage to hippocampal neurons and ultrastructural changes, and / or improve learning and memory functions and cognitive behavioral performance.

Images